Vident Advisory’s Quest Diagnostics DGX Stock Holding History

Vident Advisory’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.75M	Buy	8,252 +88	+1%	+$17.3K	0.01%	738
2026 Q1	$1.6M	Buy	8,164 +3,109	+62%	+$604K	0.01%	692
2025 Q4	$877K	Sell	5,055 -31	-0.6%	-$5.64K	0.01%	871
2025 Q3	$969K	Buy	5,086 +753	+17%	+$134K	0.01%	844
2025 Q2	$778K	Buy	4,333 +1,137	+36%	+$197K	0.01%	839
2025 Q1	$541K	Buy	3,196 +773	+32%	+$127K	0.01%	996
2024 Q4	$366K	Buy	2,423 +583	+32%	+$90.7K	0.01%	1086
2024 Q3	$286K	Buy	1,840 +171	+10%	+$25.5K	0.01%	1147
2024 Q2	$228K	Sell	1,669 -113,446	-99%	-$15.5M	0.01%	1232
2024 Q1	$15.3M	Buy	115,115 +108,523	+1,646%	+$14.1M	0.32%	92
2023 Q4	$909K	Buy	6,592 +4,871	+283%	+$640K	0.02%	591
2023 Q3	$210K	Buy	+1,721	New	+$229K	0.01%	1087

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Vident Advisory's DGX Position: Q2 2026 in Review

Vident Advisory increased its Quest Diagnostics (DGX) stake by 1.1% in Q2 2026, buying an estimated $17.3K and bringing the position to 8,252 shares worth $1.75M. The position accounts for 0.01% of the portfolio, ranked #738.

Vident Advisory first reported a position in DGX in Q3 2023 and has held it in 12 quarters since. The position peaked at $15.3M in Q1 2024. 1,111 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Vident Advisory held 8,252 shares of Quest Diagnostics worth $1.75M as of Q2 2026.
Vident Advisory bought 88 Quest Diagnostics shares in Q2 2026, an estimated $17.3K.
Quest Diagnostics made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #738 holding.
Vident Advisory first reported a position in Quest Diagnostics in Q3 2023 and has held it in 12 quarters since.
Vident Advisory's Quest Diagnostics position peaked at $15.3M in Q1 2024.
1,111 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.